These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15205383)

  • 1. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers.
    Bu HZ; Pool WF; Wu EY; Raber SR; Amantea MA; Shetty BV
    Drug Metab Dispos; 2004 Jul; 32(7):689-98. PubMed ID: 15205383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of capravirine as a CYP3A probe substrate: in vitro and in vivo metabolism of capravirine in rats and dogs.
    Bu HZ; Zhao P; Kang P; Pool WF; Wu EY; Shetty BV
    Drug Metab Dispos; 2007 Sep; 35(9):1593-602. PubMed ID: 17567732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple sequential incubation method for deconvoluting the complicated sequential metabolism of capravirine in humans.
    Bu HZ; Kang P; Zhao P; Pool WF; Wu EY
    Drug Metab Dispos; 2005 Oct; 33(10):1438-45. PubMed ID: 16006566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
    Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
    Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes.
    Bu HZ; Zhao P; Kang P; Pool WF; Wu EY
    Drug Metab Dispos; 2006 Nov; 34(11):1798-802. PubMed ID: 16914510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
    Chen L; Sabo JP; Philip E; Mao Y; Norris SH; MacGregor TR; Wruck JM; Garfinkel S; Castles M; Brinkman A; Valdez H
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2436-44. PubMed ID: 17485497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
    Li F; Wang L; Guo GL; Ma X
    Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects.
    Vermeir M; Lachau-Durand S; Mannens G; Cuyckens F; van Hoof B; Raoof A
    Drug Metab Dispos; 2009 Apr; 37(4):809-20. PubMed ID: 19131522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans.
    Shen J; Serby M; Reed A; Lee AJ; Menon R; Zhang X; Marsh K; Wan X; Kavetskaia O; Fischer V
    Drug Metab Dispos; 2016 Aug; 44(8):1139-47. PubMed ID: 27179126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.
    Denissen JF; Grabowski BA; Johnson MK; Buko AM; Kempf DJ; Thomas SB; Surber BW
    Drug Metab Dispos; 1997 Apr; 25(4):489-501. PubMed ID: 9107549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A unique example of drug metabolism: tetra- and penta-oxygenation reactions of capravirine in rats, dogs and humans.
    Bu HZ; Pool WF; Wu EY; Shetty BV
    Drug Metab Lett; 2007 Jan; 1(1):61-5. PubMed ID: 19356020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study.
    Gewurz BE; Jacobs M; Proper JA; Dahl TA; Fujiwara T; Dezube BJ
    J Infect Dis; 2004 Dec; 190(11):1957-61. PubMed ID: 15529260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Disposition, and Biotransformation of [
    Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
    Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
    Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
    Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HIV-1 non-nucleoside reverse transcriptase inhibitors (part V): capravirine and its analogues.
    Li X; Zhan P; De Clercq E; Liu X
    Curr Med Chem; 2012; 19(36):6138-49. PubMed ID: 22934811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
    Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, distribution, metabolism, and excretion of atevirdine in the rat.
    Chang M; Sood VK; Wilson GJ; Kloosterman DA; Sanders PE; Schuette MR; Judy RW; Voorman RL; Maio SM; Slatter JG
    Drug Metab Dispos; 1998 Oct; 26(10):1008-18. PubMed ID: 9763407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.